Aprea Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Aprea Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2019 to Q1 2024.
  • Aprea Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $14.7M, a 186% increase year-over-year.
  • Aprea Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $5.14M, a 653% increase from 2022.
  • Aprea Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $683K, a 60.9% decline from 2021.
  • Aprea Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $1.75M, a 1057% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $14.7M +$9.57M +186% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q1 2023 $5.14M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2020 $29.5K -$5.4M -99.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $5.43M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.